These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 16781706)
1. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Kim K; Moore DH; Makriyannis A; Abood ME Eur J Pharmacol; 2006 Aug; 542(1-3):100-5. PubMed ID: 16781706 [TBL] [Abstract][Full Text] [Related]
2. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118 [TBL] [Abstract][Full Text] [Related]
3. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. Cervetto C; Frattaroli D; Maura G; Marcoli M Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883 [TBL] [Abstract][Full Text] [Related]
4. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Raman C; McAllister SD; Rizvi G; Patel SG; Moore DH; Abood ME Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Mar; 5(1):33-9. PubMed ID: 15204022 [TBL] [Abstract][Full Text] [Related]
5. Sex-specific behavioural effects of environmental enrichment in a transgenic mouse model of amyotrophic lateral sclerosis. Stam NC; Nithianantharajah J; Howard ML; Atkin JD; Cheema SS; Hannan AJ Eur J Neurosci; 2008 Aug; 28(4):717-23. PubMed ID: 18702691 [TBL] [Abstract][Full Text] [Related]
9. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Holasek SS; Wengenack TM; Kandimalla KK; Montano C; Gregor DM; Curran GL; Poduslo JF Brain Res; 2005 May; 1045(1-2):185-98. PubMed ID: 15910777 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Haenggeli C; Julien JP; Mosley RL; Perez N; Dhar A; Gendelman HE; Rothstein JD Neurobiol Dis; 2007 Apr; 26(1):146-52. PubMed ID: 17276077 [TBL] [Abstract][Full Text] [Related]
11. Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Knippenberg S; Thau N; Dengler R; Petri S Behav Brain Res; 2010 Nov; 213(1):82-7. PubMed ID: 20450936 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis. Teng YD; Choi H; Huang W; Onario RC; Frontera WR; Snyder EY; Sabharwal S Neurosci Lett; 2006 Apr 10-17; 397(1-2):155-8. PubMed ID: 16388902 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Oliván S; Calvo AC; Rando A; Muñoz MJ; Zaragoza P; Osta R Exp Anim; 2015; 64(2):147-53. PubMed ID: 25736480 [TBL] [Abstract][Full Text] [Related]
14. Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Mahoney DJ; Rodriguez C; Devries M; Yasuda N; Tarnopolsky MA Muscle Nerve; 2004 May; 29(5):656-62. PubMed ID: 15116368 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. Chang-Hong R; Wada M; Koyama S; Kimura H; Arawaka S; Kawanami T; Kurita K; Kadoya T; Aoki M; Itoyama Y; Kato T Exp Neurol; 2005 Jul; 194(1):203-11. PubMed ID: 15899257 [TBL] [Abstract][Full Text] [Related]
16. Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta-analysis. Urbi B; Owusu MA; Hughes I; Katz M; Broadley S; Sabet A J Neurochem; 2019 Apr; 149(2):284-297. PubMed ID: 30520038 [TBL] [Abstract][Full Text] [Related]
17. A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis. Glas M; Popp B; Angele B; Koedel U; Chahli C; Schmalix WA; Anneser JM; Pfister HW; Lorenzl S Exp Neurol; 2007 Oct; 207(2):350-6. PubMed ID: 17716658 [TBL] [Abstract][Full Text] [Related]
18. New Strategy That Delays Progression of Amyotrophic Lateral Sclerosis in G1H-G93A Transgenic Mice: Oral Administration of Xanthine Oxidoreductase Inhibitors That Are Not Substrates for the Purine Salvage Pathway. Kato S; Kato M; Kusano T; Nishino T J Neuropathol Exp Neurol; 2016 Dec; 75(12):1124-1144. PubMed ID: 27815397 [TBL] [Abstract][Full Text] [Related]
19. Reassessment of motor-behavioural test analyses enables the detection of early disease-onset in a transgenic mouse model of amyotrophic lateral sclerosis. Schäfer S; Hermans E Behav Brain Res; 2011 Nov; 225(1):7-14. PubMed ID: 21723884 [TBL] [Abstract][Full Text] [Related]
20. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Pompl PN; Ho L; Bianchi M; McManus T; Qin W; Pasinetti GM FASEB J; 2003 Apr; 17(6):725-7. PubMed ID: 12586733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]